1887

Journal of General Virology header logo

Volume 89, Issue 8

Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy Free

Abstract

The 37/67 kDa laminin receptor (LRP/LR) acts as a receptor for prions providing a promising target for the treatment of prion diseases. Recently, we selected anti-LRP/LR single-chain antibodies (scFvs) and proved a reduction of the peripheral PrP propagation by passive immunotransfer into scrapie-infected mice. Here, we report the development of an gene delivery system based on adeno-associated virus (AAV) vectors expressing scFvs-S18 and -N3 directed against LRP/LR. Transduction of neuronal and non-neuronal cells with recombinant (r)AAV serotype 2 vectors encoding scFv-S18, -N3 and -C9 verified the efficient secretion of the antibodies. These vectors were administered via stereotactic intracerebral microinjection into the hippocampus of C57BL/6 mice, followed by intracerebral inoculation with 10 % RML at the same site 2 weeks post-injection of rAAV. After 90 days post-infection, scFv-S18 and -N3 expression resulted in the reduction of peripheral PrP propagation by approximately 60 and 32 %, respectively, without a significant prolongation of incubation times and survival. Proof of rAAV vector DNA in spleen samples by real-time PCR strongly suggests a transport or trafficking of rAAV from the brain to the spleen, resulting in rAAV-mediated expression of scFv followed by reduced PrP levels in the spleen most likely due to the blockage of the prion receptor LRP/LR by scFv.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83670-0
2008-08-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/8/2055.html?itemId=/content/journal/jgv/10.1099/vir.0.83670-0&mimeType=html&fmt=ahah

References

  1. Aguzzi A., Weissmann C. 1998; Prion diseases. Haemophilia 4:619–627 [CrossRef]
     [Google Scholar]
  2. Akache B., Grimm D., Pandey K., Yant S. R., Xu H., Kay M. A. 2006; The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80:9831–9836 [CrossRef]
     [Google Scholar]
  3. Barron R. M., Campbell S. L., King D., Bellon A., Chapman K. E., Williamson R. A., Manson J. C. 2007; High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo . J Biol Chem 282:35878–35886 [CrossRef]
     [Google Scholar]
  4. Bartlett J. S., Samulski R. J., McCown T. J. 1998; Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 9:1181–1186 [CrossRef]
     [Google Scholar]
  5. Coloma M. J., Hastings A., Wims L. A., Morrison S. L. 1992; Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 152:89–104 [CrossRef]
     [Google Scholar]
  6. Gauczynski S., Hundt C., Leucht C., Weiss S. 2001a; Interaction of prion proteins with cell surface receptors, molecular chaperones, and other molecules. Adv Protein Chem 57:229–272
     [Google Scholar]
  7. Gauczynski S., Peyrin J. M., Haik S., Leucht C., Hundt C., Rieger R., Krasemann S., Deslys J. P., Dormont D. other authors 2001b; The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 20:5863–5875 [CrossRef]
     [Google Scholar]
  8. Gauczynski S., Nikles D., El-Gogo S., Papy-Garcia D., Rey C., Alban S., Barritault D., Lasmezas C. I., Weiss S. 2006; The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 194:702–709 [CrossRef]
     [Google Scholar]
  9. Hacker U. T., Wingenfeld L., Kofler D. M., Schuhmann N. K., Lutz S., Herold T., King S. B., Gerner F. M., Perabo L. other authors 2005; Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med 7:1429–1438 [CrossRef]
     [Google Scholar]
  10. Hayashita-Kinoh H., Yamada M., Yokota T., Mizuno Y., Mochizuki H. 2006; Down-regulation of α -synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun 341:1088–1095 [CrossRef]
     [Google Scholar]
  11. Hirata R. K., Xu C., Dong R., Miller D. G., Ferguson S., Russell D. W. 2004; Efficient PRNP gene targeting in bovine fibroblasts by adeno-associated virus vectors. Cloning Stem Cells 6:31–36 [CrossRef]
     [Google Scholar]
  12. Kimberlin R. H., Walker C. 1977; Characteristics of a short incubation model of scrapie in the golden hamster. J Gen Virol 34:295–304 [CrossRef]
     [Google Scholar]
  13. Lasmezas C. I., Deslys J. P., Robain O., Jaegly A., Beringue V., Peyrin J. M., Fournier J. G., Hauw J. J., Rossier J. other authors 1997; Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275:402–405 [CrossRef]
     [Google Scholar]
  14. Le Gall F., Reusch U., Moldenhauer G., Little M., Kipriyanov S. M. 2004; Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J Immunol Methods 285:111–127 [CrossRef]
     [Google Scholar]
  15. Leucht C., Simoneau S., Rey C., Vana K., Rieger R., Lasmezas C. I., Weiss S. 2003; The 37 kDa/67 kDa laminin receptor is required for PrPSc propagation in scrapie-infected neuronal cells. EMBO Rep 4:290–295 [CrossRef]
     [Google Scholar]
  16. Ludewigs H., Zuber C., Vana K., Nikles D., Zerr I., Weiss S. 2007; Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther 5:613–630 [CrossRef]
     [Google Scholar]
  17. Luo J., Kaplitt M. G., Fitzsimons H. L., Zuzga D. S., Liu Y., Oshinsky M. L., During M. J. 2002; Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298:425–429 [CrossRef]
     [Google Scholar]
  18. Manson J. C., Jamieson E., Baybutt H., Tuzi N. L., Barron R., McConnell I., Somerville R., Ironside J., Will R. other authors 1999; A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J 18:6855–6864 [CrossRef]
     [Google Scholar]
  19. Morel E., Andrieu T., Casagrande F., Gauczynski S., Weiss S., Grassi J., Rousset M., Dormont D., Chambaz J. 2005; Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor. Am J Pathol 167:1033–1042 [CrossRef]
     [Google Scholar]
  20. Murdoch A. D., Liu B., Schwarting R., Tuan R. S., Iozzo R. V. 1994; Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 42:239–249 [CrossRef]
     [Google Scholar]
  21. Nelson J., McFerran N. V., Pivato G., Chambers E., Doherty C., Steele D., Timson D. J. 2008; The 67 kDa laminin receptor: structure, function and role in disease. Biosci Rep 28:33–48 [CrossRef]
     [Google Scholar]
  22. Nikles D., Vana K., Gauczynski S., Knetsch H., Ludewigs H., Weiss S. 2008; Subcellular localization of prion proteins and the 37 kDa/67 kDa laminin receptor fused to fluorescent proteins. Biochim Biophys Acta 782:335–340
     [Google Scholar]
  23. Prusiner S. B. 1998; Prions. Proc Natl Acad Sci U S A 95:13363–13383 [CrossRef]
     [Google Scholar]
  24. Reichert J. M., Rosensweig C. J., Faden L. B., Dewitz M. C. 2005; Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073–1078 [CrossRef]
     [Google Scholar]
  25. Rieger R., Edenhofer F., Lasmezas C. I., Weiss S. 1997; The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 3:1383–1388 [CrossRef]
     [Google Scholar]
  26. Rieger R., Lasmezas C. I., Weiss S. 1999; Role of the 37 kDa laminin receptor precursor in the life cycle of prions. Transfus Clin Biol 6:7–16 [CrossRef]
     [Google Scholar]
  27. Sanz L., Cuesta A. M., Compte M., Alvarez-Vallina L. 2005; Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 26:641–648 [CrossRef]
     [Google Scholar]
  28. Schmidt M., Grot E., Cervenka P., Wainer S., Buck C., Chiorini J. A. 2006; Identification and characterization of novel adeno-associated virus isolates in ATCC virus stocks. J Virol 80:5082–5085 [CrossRef]
     [Google Scholar]
  29. Sethi S., Lipford G., Wagner H., Kretzschmar H. 2002; Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 360:229–230 [CrossRef]
     [Google Scholar]
  30. Shyu W. C., Lin S. Z., Chiang M. F., Ding D. C., Li K. W., Chen S. F., Yang H. I., Li H. 2005; Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J Neurosci 25:8967–8977 [CrossRef]
     [Google Scholar]
  31. Simoneau S., Haik S., Leucht C., Dormont D., Deslys J. P., Weiss S., Lasmezas C. 2003; Different isoforms of the non-integrin laminin receptor are present in mouse brain and bind PrP. Biol Chem 384:243–246
     [Google Scholar]
  32. Summerford C., Samulski R. J. 1998; Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438–1445
     [Google Scholar]
  33. Tal J. 2000; Adeno-associated virus-based vectors in gene therapy. J Biomed Sci 7:279–291 [CrossRef]
     [Google Scholar]
  34. Vana K., Weiss S. 2006; A trans-dominant negative 37kDa/67kDa laminin receptor mutant impairs PrPSc propagation in scrapie-infected neuronal cells. J Mol Biol 358:57–66 [CrossRef]
     [Google Scholar]
  35. Vana K., Zuber C., Nikles D., Weiss S. 2007; Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Cell Mol Neurobiol 27:107–128 [CrossRef]
     [Google Scholar]
  36. Waldmann T. A. 2003; Immunotherapy: past, present and future. Nat Med 9:269–277 [CrossRef]
     [Google Scholar]
  37. Wang C., Wang C. M., Clark K. R., Sferra T. J. 2003; Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther 10:1528–1534 [CrossRef]
     [Google Scholar]
  38. Weissmann C. 2004; The state of the prion. Nat Rev Microbiol 2:861–871 [CrossRef]
     [Google Scholar]
  39. Weissmann C., Aguzzi A. 2005; Approaches to therapy of prion diseases. Annu Rev Med 56:321–344 [CrossRef]
     [Google Scholar]
  40. Wendtner C. M., Kofler D. M., Theiss H. D., Kurzeder C., Buhmann R., Schweighofer C., Perabo L., Danhauser-Riedl S., Baumert J. other authors 2002; Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 100:1655–1661
     [Google Scholar]
  41. Wrenshall L. E., Platt J. L. 1999; Regulation of T cell homeostasis by heparan sulfate-bound IL-2. J Immunol 163:3793–3800
     [Google Scholar]
  42. Wu Z., Asokan A., Samulski R. J. 2006; Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14:316–327 [CrossRef]
     [Google Scholar]
  43. Wuertzer C. A., Sullivan M. A., Qiu X., Federoff H. J. 2008; CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 16:481–486 [CrossRef]
     [Google Scholar]
  44. Xiao X., Li J., Samulski R. J. 1998; Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72:2224–2232
     [Google Scholar]
  45. Zuber C., Ludewigs H., Weiss S. 2007a; Therapeutic approaches targeting the prion receptor LRP/LR. Vet Microbiol 123:387–393 [CrossRef]
     [Google Scholar]
  46. Zuber C., Mitteregger G., Pace C., Zerr I., Kretzschmar H. A., Weiss S. 2007b; Anti-LRP antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice. Prion 1:207–212 [CrossRef]
     [Google Scholar]
  47. Zuber C., Knackmuss S., Rey C., Reusch U., Röttgen P., Fröhlich T., Arnold G. J., Pace C., Mitteregger G. & other authors (2008a). Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 45:144–151 [CrossRef]
     [Google Scholar]
  48. Zuber C., Knackmuss S., Zemora G., Reusch U., Vlasova E., Diehl D., Mick V., Hofmann K., Nikles D. & other authors (2008b). Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37-kDa/67-kDa laminin receptor. J Mol Biol 378:530–539 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83670-0
Loading
Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy
J. Gen. Virol. 89, 2055 (2008); https://doi.org/10.1099/vir.0.83670-0
/content/journal/jgv/10.1099/vir.0.83670-0
/content/journal/jgv/10.1099/vir.0.83670-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error